Expression of inflammation-related indicators in different clinical phenotypes of COPD and its relationship with the efficacy of bronchodilators and anti-inflammatory therapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029221

Enrollment

Unknown

Registered

2020-01-19

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

AECOPD group:Treatment for acute exacerbation

Healthy control group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Prior to the test, subjects must meet all of the following requirements before enrollment: 1. Aged >= 18 years, regardless of gender; 2. AECOPD patients meet the diagnostic criteria of AECOPD in the Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (2017 updated edition) : Cough, sputum, asthma symptoms, the need to change the usual medication program; non-other lung diseases caused by acute cough, sputum, wheezing; Combined with HRCT and clinical manifestations, there are three phenotypes: emphysema: grade LAA >= 1 and T/PA >= 0; chronic bronchitis: grade T/PA >= 1 and LAA >= 0; mixed type: grade LAA >= 1 and T/PA >= 1. 3. The patient can record or state the changes of the condition completely; 4. Complete clinical data and consent to participate in this study.

Exclusion criteria

Exclusion criteria: Before the test, subjects shall not be enrolled if they meet any of the following requirements: 1. Pregnant or lactating patients; 2. Patients with severe cardiopulmonary complications; 3. Autoimmune diseases, corticosteroid contraindications or drug intolerance; 4. Patients with lung tumor, pulmonary fibrosis, bronchial asthma, severe pulmonary tuberculosis, bronchiectasis and other chronic respiratory diseases; 5. Patients with other site infection or recent history of surgical trauma; 6. Patients using drugs that cause bronchospasm and/or affect lung function; 7. 30 days for emergency or hospitalization due to AECOPD; 8. The competent physician considered it inappropriate to participate in the clinical investigator.

Design outcomes

Primary

Measure	Time frame
The general information;KL-6;CRP;IL-18;TNF-a;CAT score;	—

Countries

China

Contacts

Public ContactZhang Haiqin

North Hospital of Ruijin Hospital, School of Medicine, Shanghai Jiaotong University

ocean82173g@163.com+86 13774294703

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026